Security
CLEARMIND MEDICINE INC Common Shares · CMNDD
CMNDDOTCCommon stockHistorical · closed Oct 27, 2022CIK 1892500Updated Oct 28, 2026
Current security for this SEC filerCMND · NASDAQ
CMNDD price & chart
Historical security
This listing closed Oct 27, 2022. Live provider charts are shown only for current listings.
Current security: CMND
About the company
Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech company focused on the discovery and development of non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.
In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Profit or LossUSD | — | — | — | — | — | — | -3,854,583Source | -1,071,621Source | -3,856,983Source | -5,254,678Source | -8,620,837Source | -9,410,806Source |
| Additional Financial Items | ||||||||||||
| AdjustmentsForCurrentTaxOfPriorPeriodUSD | — | — | — | — | — | — | — | — | -32,177Source | -384,109Source | — | — |
| AdjustmentsForDecreaseIncreaseInTradeAccountReceivableCAD | — | — | — | — | — | — | — | — | — | — | — | 27,214Source |
| AdjustmentsForIncomeTaxExpenseUSD | — | — | — | — | — | — | — | 39,335Source | 70,445Source | 103,879Source | — | — |
| AdjustmentsForIncreaseDecreaseInTradeAccountPayableUSD | — | — | — | — | — | — | 233,028Source | 124,094Source | 82,788Source | -198,590Source | -620,421Source | 1,246,570Source |
| AdjustmentsForSharebasedPaymentsUSD | — | — | — | — | — | — | 1,414,340Source | 380,738Source | 805,890Source | 883,872Source | 313,214Source | 1,076,438Source |
| AdjustmentsForUnrealisedForeignExchangeLossesGainsUSD | — | — | — | — | — | — | -7,649Source | 4,246Source | -3,614Source | 6,051Source | 78,171Source | — |
| GeneralAndAdministrativeExpenseUSD | — | — | 684,716Source | 1,125,365Source | 855,124Source | 980,549Source | 3,019,421Source | 1,034,736Source | 3,610,652Source | 4,362,117Source | 4,759,205Source | 4,327,334Source |
| InterestPaidClassifiedAsFinancingActivitiesCAD | — | — | — | — | — | — | — | — | — | — | — | 19,699Source |
| InterestReceivedClassifiedAsOperatingActivitiesUSD | — | — | — | — | — | — | — | 34,178Source | 132,908Source | 271,784Source | 71,733Source | — |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesUSD | — | — | — | — | — | — | 11,703Source | 10,274Source | 42,543Source | 42,587Source | 40,922Source | 77,031Source |
| ProceedsFromIssuingSharesUSD | — | — | — | — | — | — | — | — | — | 78,500Source | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General and Administrative ExpenseUSD | — | — | — | — | — | — | — | — | — | 4,362,117Source | 4,759,205Source | — |
| Additional Financial Items | ||||||||||||
| ApplicableTaxRatenumber | — | — | — | — | — | — | — | — | 0.23Source | 0.23Source | 0.23Source | — |
| BasicEarningsLossPerShareUSD per share | — | — | -0.25Source | -0.59Source | -0.16Source | -0.28Source | -3.32Source | -9.55Source | -30.35Source | -1.69Source | -42.58Source | -7.24Source |
| DepreciationRightofuseAssetsUSD | — | — | — | — | — | — | 10,567Source | 9,277Source | 38,415Source | 39,023Source | 35,381Source | 82,802Source |
| DilutedEarningsLossPerShareUSD per share | — | — | -0.25Source | -0.59Source | -0.16Source | -0.28Source | -3.32Source | -9.55Source | -30.35Source | -1.69Source | -42.58Source | -7.24Source |
| EmployeeBenefitsExpenseUSD | — | — | — | — | — | — | — | — | 66,175Source | 57,340Source | 37,838Source | 125,975Source |
| ExpenseFromSharebasedPaymentTransactionsWithEmployeesUSD | — | — | — | — | — | — | — | — | 81,786Source | 132,502Source | 243,717Source | — |
| FinanceCostsCAD | — | — | — | — | — | — | — | — | — | — | — | 837,473Source |
| GeneralAndAdministrativeExpenseUSD | — | — | 684,716Source | 1,125,365Source | 855,124Source | 980,549Source | 3,019,421Source | 1,034,736Source | 3,610,652Source | 4,362,117Source | 4,759,205Source | 4,327,334Source |
| IncomeTaxExpenseContinuingOperationsUSD | — | — | 8,258Source | 42,590Source | 20,658Source | 36,756Source | 3,960Source | 39,335Source | 70,445Source | 377,966Source | 17,372Source | 40,754Source |
| InterestExpenseUSD | — | — | — | — | — | — | — | — | 3,857Source | 5,386Source | — | 19,678Source |
| InterestExpenseOnLeaseLiabilitiesUSD | — | — | — | — | — | — | — | 1,278Source | 3,858Source | 5,386Source | 40,922Source | 96,730,000,000Source |
| NetForeignExchangeLossUSD | — | — | — | — | — | — | — | — | — | — | 3,684Source | 45,605Source |
| OtherIncomeUSD | — | — | — | — | — | — | — | — | — | — | 16,555Source | — |
| PostemploymentBenefitExpenseDefinedContributionPlansUSD | — | — | — | — | — | — | — | — | — | — | 13,988Source | 42,526Source |
| ProfessionalFeesExpenseUSD | — | — | — | — | — | — | — | — | 1,640,621Source | 1,998,625Source | 2,210,795Source | 1,493,024Source |
| ProfitLossBeforeTaxUSD | — | — | -1,305,334Source | -2,051,327Source | -763,270Source | -871,461Source | -3,850,623Source | -1,032,286Source | -3,786,538Source | -4,876,712Source | -8,603,465Source | -9,370,052Source |
| ProfitLossFromOperatingActivitiesCAD | — | — | — | — | — | — | — | — | — | — | — | -8,532,579Source |
| ResearchAndDevelopmentExpenseUSD | — | — | 723,048Source | 345,883Source | 451,857Source | 322,956Source | 640,494Source | 461,438Source | 2,056,525Source | 1,382,808Source | 1,544,229Source | 4,205,245Source |
Offerings
Registration 333-291817
Registration 333-295455
Registration 333-293521
Registration 333-276913
Registration 333-290404
Filing attachments
ea030979801ex99-1.htm · 6-K · 2026-10-27
Exhibit 99.1 Clearmind Successfully Completes Patient Recruitment for the First Alcohol Use Disorder Cohort of its CMND-100 Phase I/IIa Clinical Trial Milestone advances Clearmind’s clinical program as the company continues to develop CMND-100 as a potential novel therapeutic candidate for alcohol use disorder Vancouver, Canada, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biopharmaceutical company advancing non-hall…
Read attachment ↗ea030833702ex99-1.htm · 6-K · 2026-10-13
Exhibit 99.1 Clearmind: Charging Robotics Launches Next-Generation Automated EV-Charging Technology for Robotaxis and Autonomous Fleets Vancouver, Canada, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation psychedelic, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced that …
Read attachment ↗ea030805601ex99-1.htm · 6-K · 2026-10-08
Exhibit 99.1 Clearmind Announces Patent Publication in Japan Covering Treatment for Neurological Movement Disorder Published patent application covers 3-MMC-based treatment of dyskinesia, including in combination with Palmitoylethanolamide (PEA) Vancouver, Canada, Oct. XX, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (the “Company”), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogen for scalable treatment of neuropsyc…
Read attachment ↗ea030794301ex99-1.htm · 6-K · 2026-10-07
Exhibit 99.1 Clearmind Advances Dialogue with U.S. Federal Government on Psychedelic Therapies, Submitting Recommendations to FDA Company Calls for Consideration of New Regulatory Pathways and Cost Saving of Non-Hallucinogenic Neuroplastogens for Alcohol Use Disorder Vancouver, Canada, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (the “Company”), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogens for scalable…
Read attachment ↗ea030637501ex99-1.htm · 6-K · 2026-09-23
Exhibit 99.1 Clearmind Enhances U.S. IP Presence with Publication of Three Patent Applications Covering LSD, Ketamine and Ibogaine Combinations The covered applications address potential therapeutic uses across a range of indications, including mental health disorders, such as depression and PTSD as well as substance use disorders Vancouver, Canada, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (the “Company”), a clinical-stage biopharmaceutical company advancing n…
Read attachment ↗ea030582601ex99-1.htm · 6-K · 2026-09-17
Exhibit 99.1 Clearmind Medicine Delivers Briefing to FDA Following Invitation to Historic Psychedelic Hearing in Washington, D.C. Mary-Elizabeth Gifford, Chief of Global Impact at Clearmind Medicine, spoke on patient access and shared insights from Clearmind’s clinical trial at Yale and Johns Hopkins Vancouver, Canada, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (the “Company” or “Clearmind”), a clinical-stage biopharmaceutical company advancing non-hallucinogeni…
Read attachment ↗